Synergistic upregulation of PD‑L1 in tumor cells and CD39 in tumor‑infiltrating CD8<sup>+</sup> T cells leads to poor prognosis in patients with hepatocellular carcinoma

Kang,Xi; Zhao,Sinan; Lin,Shan; Li,Jing; Wang,Shunxiang

doi:10.3892/ol.2024.14501

August-2024 Volume 28 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2024 Volume 28 Issue 2

Full Size Image

Article Open Access

Synergistic upregulation of PD‑L1 in tumor cells and CD39 in tumor‑infiltrating CD8⁺ T cells leads to poor prognosis in patients with hepatocellular carcinoma

Authors:
- Xi Kang
- Sinan Zhao
- Shan Lin
- Jing Li
- Shunxiang Wang
View Affiliations / Copyright

Affiliations: Department of Hepatobiliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Heibei 050000, P.R. China

Copyright: © Kang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 368
|
Published online on: June 12, 2024

https://doi.org/10.3892/ol.2024.14501
Expand metrics +

Abstract

The immune escape of tumor cells and functional status of tumor‑infiltrating T cells may serve pivotal roles in the tumor immune microenvironment and progression of hepatocellular carcinoma (HCC). The present study enrolled 91 patients with HCC and examined programmed cell death ligand 1 (PD‑L1) expression in tumor cells and CD39 expression in tumor‑infiltrating CD8+ T cells in patient samples using multiplex immunofluorescence assays. The impact of PD‑L1 and CD39 expression levels on the prognosis of patients with HCC was investigated utilizing Kaplan‑Meier analyses. The individual upregulation of PD‑L1 in tumor cells, as well as the individual upregulation of CD39 expression in tumor‑infiltrating CD8⁺ T cells did not significantly affect the prognosis of patients with HCC. However, the simultaneous upregulation of both PD‑L1 in tumor cells and CD39 in tumor‑infiltrating CD8⁺ T cells was associated with reduced overall survival in patients with HCC. Therefore, the results of the present study suggested that the interplay between tumor cell immune escape and tumor‑infiltrating immune cell functional status within the tumor immune microenvironment may have had a substantial impact on the prognosis of patients with HCC. Mechanistically, increased expression levels of PD‑L1 in tumor cells may improve the immune escape capacity of tumors, whilst upregulation of CD39 in tumor‑infiltrating T cells may be associated with T cell exhaustion. Therefore, the upregulation of PD‑L1 expression in tumor cells, in conjunction with the exhaustion of tumor‑infiltrating CD8⁺ T cells, could serve as a future potential prognostic indicator of patients with HCC.

View Figures

View References

1	Block TM, Mehta AS, Fimmel CJ and Jordan R: Molecular viral oncology of hepatocellular carcinoma. Oncogene. 33:5093–5107. 2003. View Article : Google Scholar : PubMed/NCBI
2	McGlynn KA, Petrick JL and El-Serag HB: Epidemiology of hepatocellular carcinoma. Hepatology. 73 (Suppl 1):S4–S13. 2021. View Article : Google Scholar
3	Han Z, Yang F, Zhang Y, Wang J, Ni Q, Zhu H, Zhou X, Gao H and Lu J: Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study. Front Oncol. 12:10299512022. View Article : Google Scholar : PubMed/NCBI
4	Chew V, Lai L, Pan L, Lim CJ, Li J, Ong R, Chua C, Leong JY, Lim KH, Toh HC, et al: Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci USA. 114:E5900–E5909. 2017. View Article : Google Scholar : PubMed/NCBI
5	Yu P and Fu YX: Tumor-infiltrating T lymphocytes: Friends or foes? Lab Invest. 86:231–245. 2006. View Article : Google Scholar : PubMed/NCBI
6	Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpréville V, Validire P, Besse B and Mami-Chouaib F: CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 194:3475–3486. 2015. View Article : Google Scholar : PubMed/NCBI
7	Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, Keshavjee S, Johnston MR and de Perrot M: Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 135:823–829. 2008. View Article : Google Scholar : PubMed/NCBI
8	Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
9	Jiang Y, Li Y and Zhu B: T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 6:e17922015. View Article : Google Scholar : PubMed/NCBI
10	Antonioli L, Pacher P, Vizi ES and Haskó G: CD39 and CD73 in immunity and inflammation. Trends Mol Med. 19:355–367. 2013. View Article : Google Scholar : PubMed/NCBI
11	Canale FP, Ramello MC, Núñez N, Araujo Furlan CL, Bossio SN, Gorosito Serrán M, Tosello Boari J, Del Castillo A, Ledesma M, Sedlik C, et al: CD39 Expression defines cell exhaustion in tumor-infiltrating CD8⁺ T cells. Cancer Res. 78:115–128. 2018. View Article : Google Scholar : PubMed/NCBI
12	Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, et al: Bystander CD8⁺ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 557:575–579. 2018. View Article : Google Scholar : PubMed/NCBI
13	Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, Kuchroo VK, Freeman GJ and Sharpe AH: PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA. 101:10691–10696. 2004. View Article : Google Scholar : PubMed/NCBI
14	Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999. View Article : Google Scholar : PubMed/NCBI
15	Jiang Y, Chen M, Nie H and Yuan Y: PD-1 and PD-L1 in cancer immunotherapy: Clinical implications and future considerations. Hum Vaccin Immunother. 15:1111–1122. 2019. View Article : Google Scholar : PubMed/NCBI
16	Dolina JS, Van Braeckel-Budimir N, Thomas GD and Salek-Ardakani S: CD8⁺ T cell exhaustion in cancer. Front Immunol. 12:7152342021. View Article : Google Scholar : PubMed/NCBI
17	Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, Chung JC, Kim HC, Lee MS and Baek MJ: Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat. 49:246–254. 2017. View Article : Google Scholar : PubMed/NCBI
18	Guo M, Yuan F, Qi F, Sun J, Rao Q, Zhao Z, Huang P, Fang T, Yang B and Xia J: Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8⁺T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med. 18:3062020. View Article : Google Scholar : PubMed/NCBI
19	Huang CY, Wang Y, Luo GY, Han F, Li YQ, Zhou ZG and Xu GL: Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma. J Immunother. 40:323–333. 2017. View Article : Google Scholar : PubMed/NCBI
20	Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, Toshima T, Harada N, Kohashi K, Oda Y and Mori M: CMTM6 stabilizes PD-L1 expression and is a new prognostic impact factor in hepatocellular carcinoma. Hepatol Commun. 5:334–348. 2021. View Article : Google Scholar : PubMed/NCBI
21	Hu K, Wang ZM, Li JN, Zhang S, Xiao ZF and Tao YM: CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage. Transl Oncol. 11:552–558. 2018. View Article : Google Scholar : PubMed/NCBI
22	Wang Q, Liu F and Liu L: Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine (Baltimore). 96:e63692017. View Article : Google Scholar : PubMed/NCBI
23	Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, et al: BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 76:681–693. 2022. View Article : Google Scholar : PubMed/NCBI
24	Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, Bie P, Liu L, Wen T, Kuang M, et al: Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Liver Cancer. 12:405–444. 2023. View Article : Google Scholar : PubMed/NCBI
25	Huang A, Yang XR, Chung WY, Dennison AR and Zhou J: Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 5:1462020. View Article : Google Scholar : PubMed/NCBI
26	Xing R, Gao J, Cui Q and Wang Q: Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol. 12:7832362021. View Article : Google Scholar : PubMed/NCBI
27	Ribas A and Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science. 359:1350–1355. 2018. View Article : Google Scholar : PubMed/NCBI
28	Han Y, Liu D and Li L: PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 10:727–742. 2020.PubMed/NCBI
29	Wang S, Yuan B, Wang Y, Li M, Liu X, Cao J, Li C and Hu J: Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: A meta-analysis. Int J Colorectal Dis. 36:117–130. 2021. View Article : Google Scholar : PubMed/NCBI
30	Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A and Walker J: PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 112:200–215. 2017. View Article : Google Scholar : PubMed/NCBI
31	Zhang M, Sun H, Zhao S, Wang Y, Pu H, Wang Y and Zhang Q: Expression of PD-L1 and prognosis in breast cancer: A meta-analysis. Oncotarget. 8:31347–31354. 2017. View Article : Google Scholar : PubMed/NCBI
32	Wherry EJ and Kurachi M: Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI

Journals